Innate Pharma SA (IPHA) — key financial figures for fiscal year 2025 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2025)

€9.0M

Net Income/Loss (FY2025)

-€49.2M

Total Assets (FY2025)

€62.7M

Total Equity (FY2025)

-€21.7M

Cash Flows from Operating Activities (FY2025)

-€52.8M

Source: Innate Pharma SA 20-F filing (FY2025). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.